PANVACTM has been shown to enhance CEA and MUC1-specific cytotoxic T-lymphocyte response [68] in preclinical models and has already been tested in diverse tumor entities including pancreatic [69] and colorectal cancer [70]. The gene discussed is MUC1; the disease is neoplasm.